Study guide

3.3 Social Determinants of Health and Disparities in Infectious Diseases

Board Certified Infectious Diseases Pharmacist BCIDP

Track your progress as you read

Finished sections get a check mark.

1 Causes of Infectious Diseases

1.1 Bacterial Pathogens: Gram-Positive, Gram-Negative, and Atypical Organisms 1.2 Viral Pathogens: Respiratory, Herpesviruses, Hepatitis, and Emerging Viruses 1.3 Fungal Pathogens: Yeasts, Molds, and Dimorphic Fungi 1.4 Parasitic and Vector-Borne Pathogens: Protozoa and Helminths

2 Microbiology Diagnostics, Resistance & Host Response

2.1 Diagnostic Microbiology: Phenotypic, Molecular, and Rapid Diagnostic Methods 2.2 Molecular Mechanisms of Antimicrobial Resistance 2.3 Microbial Virulence Factors, Toxins, and Biofilm Dynamics 2.4 Host Immune Response to Infection and Immunopathology

3 Clinical Assessment & Diagnostic Evaluation

3.1 Clinical Assessment, Infection Screening, and Severity Stratification 3.2 Diagnostic Biomarkers and Clinical Laboratory Interpretation 3.3 Social Determinants of Health and Disparities in Infectious Diseases

4 Pharmacokinetics, Pharmacodynamics & Special Populations

4.1 Pharmacokinetic and Pharmacodynamic Optimization of Antimicrobials 4.2 Host and Environmental Risk Factors for Infection 4.3 Antimicrobial Dosing and Considerations in Special Populations

5 Respiratory and Skin/Soft Tissue Infections

5.1 Pharmacotherapy of Upper and Lower Respiratory Tract Infections 5.2 Pharmacotherapy of Skin and Soft Tissue Infections

6 Cardiovascular, Bone, and Joint Infections

6.1 Pharmacotherapy of Infective Endocarditis and CIED Infections 6.2 Pharmacotherapy of Osteomyelitis, Septic Arthritis, and PJI

7 Central Nervous System and Abdominal Infections

7.1 Pharmacotherapy of Central Nervous System Infections 7.2 Pharmacotherapy of Intra-abdominal, Hepatic, and GI Infections

8 Urologic, Gynecologic, and Sexually Transmitted Infections

8.1 Pharmacotherapy of Urinary Tract and Gynecologic Infections 8.2 Pharmacotherapy of Sexually Transmitted Infections

9 HIV Infection and Opportunistic Infections

9.1 Antiretroviral Therapy and Management of HIV-1 Infection 9.2 Prophylaxis and Management of HIV-Associated Opportunistic Infections

10 Infections in Immunocompromised Hosts and Complex Syndromes

10.1 Infections in Solid Organ Transplant and Hematologic Malignancy 10.2 Sepsis, Septic Shock, and Systemic Complications

11 Medication Administration and Adjunctive Therapies

11.1 Antimicrobial Administration, Vascular Access, and Stability 11.2 Adjunctive Pharmacotherapies and Supportive Care in Serious Infections 11.3 Assessment of Therapeutic Outcomes and Infection Failure

12 Therapeutic Drug Monitoring, Toxicity, and De-escalation

12.1 Therapeutic Drug Monitoring and Precision Pharmacokinetics 12.2 Antimicrobial Adverse Drug Events and High-Risk Drug Interactions 12.3 Antimicrobial De-escalation and IV-to-Oral Transition Strategies

13 Care Transitions, Patient Counseling & Travel Medicine

13.1 Outpatient Parenteral and Complex Oral Antimicrobial Therapy (OPAT/COPAT) 13.2 Patient and Caregiver Counseling, Education, and Adherence 13.3 Travel Medicine, Immunizations, and Prophylactic Regimens

14 Antimicrobial Stewardship Operations, Metrics & Resistance

14.1 Antimicrobial Stewardship Core Elements and Regulatory Mandates 14.2 Stewardship Metrics: Days of Therapy (DOT), DDD, and SAAR 14.3 Surveillance and Tracking of Antimicrobial Resistance Patterns 14.4 Cumulative Antibiogram Construction and CLSI M39 Analysis

15 Formulary Management, Infection Prevention & Population Health

15.1 Antimicrobial Formulary Management and Restriction Strategies 15.2 Public Health, Disease Reporting, and Adult Immunization Strategies 15.3 Healthcare Infection Prevention and Environmental Transmission

16 Literature Evaluation, Informatics & Quality Improvement

16.1 Infectious Diseases Information Resources, Databases, and Clinical Guidelines 16.2 Critical Literature Evaluation and Biostatistical Interpretation 16.3 Quality Improvement Methodologies and Medication Safety in ID 16.4 Clinical Informatics, Decision Support Systems, and Automated Alerts

3.3 Social Determinants of Health and Disparities in Infectious Diseases

Key Takeaways Explain This Topic AI

Social determinants of health (SDOH)—including housing instability, poverty, food insecurity, and transportation access—drive infectious disease transmission, delayed diagnosis, and treatment attrition.

Profound structural disparities characterize the epidemiology of HIV, viral hepatitis, tuberculosis, syphilis, and multidrug-resistant pathogens, disproportionately burdening marginalized racial groups, rural populations, and sexual minorities.

Novel antimicrobials and long-acting regimens incur severe financial and administrative barriers; ID pharmacists lead prior authorization navigation, manufacturer patient assistance programs (PAP), and 340B safety-net access.

Federal Anti-Kickback Statute regulations strictly prohibit manufacturer co-pay discount cards for Medicare and Medicaid beneficiaries, necessitating referrals to independent non-profit co-pay foundations.

Low-barrier harm reduction care—including syringe services programs, naloxone distribution, oral step-down regimens (COPAT), and long-acting lipoglycopeptides—dramatically improves infection cure in persons who inject drugs (PWID).

Last updated: October 2026

Framework of Social Determinants of Health in Infectious Diseases

Health outcomes in infectious diseases are fundamentally governed by the social, economic, and physical conditions in which individuals live. The Healthy People 2030 framework categorizes Social Determinants of Health (SDOH) into five structural domains:

  • Economic Stability (poverty, employment, food security, housing stability)
  • Education Access and Quality (health literacy, language proficiency, early childhood education)
  • Healthcare Access and Quality (health insurance coverage, health literacy, provider access)
  • Neighborhood and Built Environment (quality of housing, overcrowding, clean water, air quality)
  • Social and Community Context (discrimination, incarceration, social cohesion, civic participation)
  • Biological and Clinical Mechanisms of SDOH Vulnerability

Housing Instability and Homelessness: Crowded shelter living accelerates transmission of airborne pathogens ( Mycobacterium tuberculosis , influenza, SARS-CoV-2) and ectoparasites (scabies, body lice carrying Bartonella quintana ). Unhoused patients lack access to clean water, sanitary wound care, electricity for refrigeration of reconstituted oral suspensions (e.g., amoxicillin-clavulanate), and secure storage for medications, frequently leading to stolen or damaged antimicrobial supplies.

Food Insecurity: Macronutrient and micronutrient deficiencies impair cellular and humoral immunity, blunt phagocytic oxidative burst, and predispose to severe opportunistic infections. Additionally, certain oral medications require co-administration with high-calorie meals to achieve adequate systemic exposure (e.g., rilpivirine requires >=390 kcal, atazanavir requires food, and oral posaconazole suspension requires fatty meals); food-insecure patients face therapeutic failure from subtherapeutic absorption.

Health Literacy Deficits: Complex multi-drug regimens—such as four-drug therapy for active tuberculosis (rifampin, isoniazid, pyrazinamide, ethambutol) or multi-agent antiretroviral therapy—require nuanced comprehension. Patients with limited health literacy are vulnerable to premature antibiotic cessation upon symptomatic improvement, inadvertent dose omission, or sharing antibiotics with family members, accelerating the selection of resistant strains.

Transportation and Geographic Barriers: Lack of reliable transportation directly correlates with missed outpatient parenteral antimicrobial therapy (OPAT) clinic checks, unmonitored laboratory toxicities (e.g., missed aminoglycoside troughs or linezolid CBCs), and delayed presentation for fulminant infections.

Disparities in Endemic Infectious Diseases and Antimicrobial Access

Deep-seated structural inequities and historical medical disenfranchisement create stark disparities in infection burden across the United States.

1. Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infections (STIs)

Disproportionate HIV Incidence: Although effective antiretroviral therapy can achieve undetectable viral loads ( Undetectable = Untransmittable , U=U), new HIV diagnoses are heavily concentrated among Black/African American and Hispanic/Latino men who have sex with men (MSM), Black cisgender women, and transgender individuals. Over 50% of new HIV infections in the United States occur in the Southern states, driven by non-expansion of Medicaid, rural hospital closures, poverty, and pervasive social stigma.

Pre-Exposure Prophylaxis (PrEP) Inequity: While approximately 60% of eligible White individuals at risk for HIV receive PrEP (tenofovir disoproxil fumarate/emtricitabine, tenofovir alafenamide/emtricitabine, or cabotegravir extended-release injection), less than 15% of eligible Black and Hispanic individuals receive PrEP prescriptions, highlighting severe prescribing disparities and clinic access deserts.

Resurgence of Congenital Syphilis: Syphilis cases have reached multi-decade highs, accompanied by catastrophic surges in congenital syphilis. These cases are concentrated among mothers experiencing housing instability, methamphetamine or opioid use disorder, and absence of prenatal care due to systemic barriers.

2. Viral Hepatitis Syndemic

Hepatitis C Virus (HCV): The opioid epidemic has fueled an exponential rise in acute HCV infections among young adults, particularly in rural Appalachia, the Midwest, and Western states. Historically, many state Medicaid programs enforced discriminatory coverage restrictions—requiring documented 6-month sobriety, negative toxicological screens, or advanced hepatic fibrosis (Metavir F3 or F4 stage)—before authorizing curative direct-acting antiviral (DAA) therapy. Infectious diseases pharmacists have played a central role in successfully advocating for the elimination of these punitive barriers, enabling universal "test-and-treat" access.

3. Tuberculosis (TB)

Over 70% of reported active TB cases in the United States occur among foreign-born individuals, reflecting high prevalence in countries of origin and structural gaps in overseas and domestic screening. Undocumented immigrants face acute fears of legal enforcement or deportation, resulting in delayed presentation until advanced cavitary disease develops. Overcoming this barrier requires confidential, community-based public health clinics and low-barrier short-course latent TB infection (LTBI) treatment regimens (e.g., 3 months of once-weekly isoniazid plus rifapentine [3HP] or 4 months of daily rifampin [4R]) to optimize completion rates.

4. Multidrug-Resistant Organisms (MDROs)

Pathogens such as MRSA, carbapenem-resistant Enterobacterales (CRE), and Candida auris disproportionately concentrate in under-resourced public safety-net institutions and understaffed skilled nursing facilities. These facilities often lack dedicated infection prevention specialists, rapid molecular diagnostic platforms, and private isolation rooms, compounding transmission among chronically ill, medically complex patients.

Medication Affordability and Administrative Access Barriers

The exorbitant cost of novel antimicrobials creates acute discharge bottlenecks and therapeutic disparities.

Financial Landscape of Novel Antimicrobials

Novel branded antimicrobials engineered for multidrug-resistant pathogens—such as ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, cefiderocol, eravacycline, isavuconazonium sulfate, and long-acting antiretrovirals (cabotegravir/rilpivirine)—often carry wholesale acquisition costs exceeding $1,000 to $1,500 per day or $25,000 to $40,000 per treatment course. Uninsured and underinsured patients cannot afford these medications without dedicated health-system support.

Prior Authorization (PA) Navigation and Pharmacist Advocacy

Transitioning a hospitalized patient to outpatient oral or intravenous therapy frequently encounters insurer rejections, formularies requiring fail-first trials of ineffective generic agents, or prolonged PA review periods (72 hours to 2 weeks):

Pharmacist-Led Appeal Strategy: The infectious diseases pharmacist must proactively compile comprehensive appeal packets containing pathogen identification, susceptibility testing demonstrating resistance to generic alternatives, clinical guidelines supporting the chosen agent, and documented risks of treatment failure or nephrotoxicity with older second-line agents (e.g., polymyxins or aminoglycosides).

Urgent/Peer-to-Peer Review: Escalating to urgent peer-to-peer reviews prevents unnecessary inpatient hospitalization days spent awaiting administrative clearance.

Navigation of Patient Assistance Programs (PAP) and Legal Constraints

Assistance Pathway Eligible Patient Population Mechanism & Regulatory Constraints

Manufacturer Co-Pay Cards Exclusively Commercially Insured patients Manufacturer offsets out-of-pocket prescription co-payments (e.g., reducing monthly co-pay to $5-$25).

Federal Anti-Kickback Statute Constraint Patients enrolled in Federal Healthcare Programs (Medicare Part D, Medicare Advantage, Medicaid, TRICARE, VA) STRICTLY PROHIBITED BY LAW (42 U.S.C. § 1320a-7b). Utilizing manufacturer co-pay discount cards for government-insured patients is considered an illegal kickback and inducement.

Independent Charitable Copay Foundations Underinsured Medicare/Medicaid patients Independent non-profit 501(c)(3) foundations (e.g., Patient Access Network [PAN] Foundation, HealthWell Foundation) provide grant funding for specific disease states. Complies with federal anti-kickback statutes.

Manufacturer Patient Assistance Programs (PAP) Uninsured or significantly underinsured individuals Pharmaceutical manufacturers provide free medication to patients meeting income thresholds (typically <300% to 500% of the Federal Poverty Level). Requires extensive application and financial documentation.

340B Drug Pricing Program Outpatients treated at designated safety-net covered entities Federal program allowing safety-net hospitals and federally qualified health centers (FQHCs) to purchase medications at steep discounts (25% to 50% below wholesale), expanding access for vulnerable outpatients.

Warning

Under the federal Anti-Kickback Statute, pharmacists and clinicians must NEVER apply pharmaceutical manufacturer co-pay coupons or discount cards to prescriptions billed to Medicare Part D or Medicaid. Violations carry substantial civil and criminal penalties. For government-insured patients with unaffordable co-pays, pharmacists must utilize independent charitable disease foundations or 340B safety-net programs.

Harm Reduction and Low-Barrier Infectious Disease Care

Persons who inject drugs (PWID) experience disproportionate rates of severe invasive bacterial and fungal infections, including infective endocarditis (tricuspid, mitral, and aortic valves), spinal epidural abscesses, vertebral osteomyelitis, septic arthritis, mycotic aneurysms, and polymicrobial necrotizing fasciitis.

Principles of Harm Reduction

Harm reduction is an evidence-based, compassionate public health approach that focuses on minimizing the adverse negative consequences of substance use without demanding immediate abstinence as an absolute prerequisite for medical care.

Core Harm Reduction Modalities in Infectious Diseases:

Syringe Services Programs (SSPs): Providing sterile syringes, cookers, sterile water, and filters reduces transmission of HIV and HCV by >50%. Studies demonstrate that SSPs do NOT increase drug use or crime, and individuals who utilize SSPs are five times more likely to enter substance use treatment .

Overdose Prevention Education and Naloxone Co-Prescribing: Routine co-dispensing of intranasal naloxone and educational counseling on rescue breathing.

Fentanyl and Xylazine Test Strips: Equipping patients with point-of-use diagnostic strips to identify lethal adulterants in illicit drug supplies.

Linkage to Medications for Opioid Use Disorder (MOUD): Initiating buprenorphine or methadone during acute inpatient hospitalization for serious infections dramatically decreases mortality, reduces against-medical-advice (AMA) discharge rates, and promotes infection completion.

Low-Barrier and Flexible Antimicrobial Delivery in PWID

Historically, PWID were systematically excluded from standard Outpatient Parenteral Antimicrobial Therapy (OPAT) due to provider concerns regarding central venous catheter tampering, leading to forced 6-week hospitalizations, punitive discharge policies, or AMA departures with incomplete therapy.

Modern evidence-based alternatives to traditional PICC-line OPAT:

Long-Acting Lipoglycopeptides (Dalbavancin and Oritavancin):

Possess exceptional terminal half-lives (dalbavancin half-life ~14 days; oritavancin half-life ~10 days) and potent bactericidal activity against MRSA, MSSA, and Streptococcus species.

Administering dalbavancin as a single 1,500 mg IV infusion (or two 1,125 mg infusions separated by 1 week) provides sustained, therapeutic bactericidal serum and bone concentrations for up to 6 to 8 weeks.

Eliminates the need for any indwelling central venous catheter, completely removing vascular access risks, line tampering, and hospitalization requirements. Highly effective for osteomyelitis, complicated skin structure infections, and right-sided infective endocarditis in PWID and unstably housed individuals.

Complex Outpatient Oral Antimicrobial Therapy (COPAT):

Landmark multicenter clinical trials—including OVIVA (oral vs. intravenous antibiotics for bone and joint infections) and POET (partial oral treatment of endocarditis)—demonstrated that transitioning clinically stable patients with bacteremic clearance to highly bioavailable oral regimens (e.g., fluoroquinolones, linezolid, trimethoprim-sulfamethoxazole, rifampin combinations) is non-inferior to prolonged intravenous catheter therapy .

Oral step-down regimens provide a transformative, patient-centered option for individuals who cannot safely manage intravenous catheters.

Culturally Competent Communication and Overcoming Stigma

Medical mistrust among PWID and historically marginalized populations is fueled by previous experiences of discrimination, undertreated withdrawal, and dismissive clinical encounters.

Person-First, Non-Stigmatizing Language:

Use "person who injects drugs" or "person with opioid use disorder" instead of "addict" , "substance abuser" , or "junkie" .

Use "toxicology screen positive for..." instead of "dirty urine" .

Use "person with HIV" instead of "HIV-infected patient" .

Trauma-Informed Care: Acknowledging past trauma, prioritizing patient autonomy, treating acute pain and opioid withdrawal aggressively from the moment of presentation, and providing low-barrier, walk-in infectious disease clinic services fosters trust, therapeutic engagement, and long-term infection eradication.